AMIX (Autonomix Medical) Current Deferred Taxes Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $5.51
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical Current Deferred Taxes Liabilities?

Autonomix Medical AMIX -4.42% 15 Current Deferred Taxes Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Autonomix Medical's current deferred tax liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Autonomix Medical Current Deferred Taxes Liabilities Related Terms

Autonomix Medical Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Autonomix Medical's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical Current Deferred Taxes Liabilities Chart

Autonomix Medical Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Current Deferred Taxes Liabilities
0.00 0.00 0.00 0.00

Autonomix Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AMIX
15GF Score
Autonomix Medical Inc AMIX
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Autonomix Medical (AMIX) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Mar. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Autonomix Medical and its competitors.
Is Autonomix Medical's Current Deferred Taxes Liabilities too high?
Autonomix Medical's current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's Current Deferred Taxes Liabilities compare to BJDX and LUDG?
Autonomix Medical's Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Medical Devices & Instruments company?
A good Current Deferred Taxes Liabilities depends on the Medical Devices & Instruments industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Autonomix Medical and its competitors. Autonomix Medical's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current Current Deferred Taxes Liabilities of $0.00 Mil. The current Current Deferred Taxes Liabilities is $0.00 Mil. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.51
Price